Allurion Technologies (ALUR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $5.4 million, including a $1.2 million recall adjustment and the suspension of sales in France, with macroeconomic headwinds and competition from GLP-1 drugs impacting key markets.

• AI product revenues (Virtual Care Suite) grew over 80% year-over-year, with strong traction in the U.S. and Europe, especially among GLP-1 patients.

• Major restructuring in November 2024 reduced workforce by about 50% to align costs, with a five-pillar strategy for 2025 focused on commercial realignment, scaling AI, FDA approval, ex-U.S. profitability, and resuming France commercialization.

• Sales of the Allurion Balloon in France were suspended in August 2024 by the French regulator, requiring a remediation plan and impacting revenue.

• The company faces NYSE delisting risks due to non-compliance with minimum share price and market capitalization standards.

Financial highlights

• Q3 2024 revenue was $5.4 million, down from $18.2 million in Q3 2023, due to destocking, France suspension, and credit risk management.

• Gross profit margin fell to 58% from 77% year-over-year, mainly due to the France recall and lower production volumes.

• Sales and marketing expenses dropped to $5.2 million from $14.0 million, and R&D expenses decreased to $3.2 million.

• Loss from operations improved to $12.3 million from $26.2 million in Q3 2023, aided by lower operating costs.

• Net loss for Q3 2024 was $9.0 million, or $(0.14) per share, compared to $21.6 million, or $(0.54) per share, in Q3 2023.

Outlook and guidance

• 2024 revenue is expected to be $30–$35 million, with flat procedure volume versus 2023.

• Operating expenses are projected to decrease by about 50% in 2025 due to restructuring and headcount reduction.

• Targeting ex-U.S. profitability and Adjusted EBITDA break-even by end of 2025.

• U.S. revenue in 2025 will be limited to the Virtual Care Suite pending FDA approval for the balloon.

• Management expects continued operating losses and negative cash flows, with substantial doubt about the company's ability to continue as a going concern over the next year.